ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

A Comparison of Medical Costs Among ABO-Compatible, -Incompatible, and -Minor Mismatched Living Kidney Transplantation: A Single-Center Study.

D. Fujimori, M. Okumi, K. Ungami, H. Ishida, K. Tanabe.

Urology, Tokyo Women's Medical University, Tokyo, Japan

Meeting: 2017 American Transplant Congress

Abstract number: B181

Keywords: Economics, Kidney transplantation

Session Information

Date: Sunday, April 30, 2017

Session Name: Poster Session B: Kidney Immunosuppression: Induction Therapy

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall D1

Related Abstracts
  • Excellent Long-Term Outcome of ABO-Incompatible Living Donor Kidney Transplantation; a Single Center Experience for over 20 Years
  • ABO-Incompatible Living Kidney Transplantation at Multicenter Japanese Case Series: Evolution of Outcomes and Immunosuppressive Management.

[Background]

ABO-incompatible living kidney transplantation (ABO-ILKT) is considered an effective alternative to deceased kidney transplantation. Although ABO-ILKT required extra strategies and suffered extra risks across ABO blood type barrier compared to ABO-compatible or minor mismatched LKT (ABO-CLKT or -MLKT), there has been an evolution in ABO-ILKT leading to a simplification of protocols over the last decade. However, in the US, the infrequent use of ABO-ILKT may reflect concerns about the medical costs of ABO-ILKT.

ABO-ILKT has been performed at our institution since 1989 to broaden the range of donor types used for LKT. Our distinctive immunosuppressive regimen and desensitization protocol for ABO-ILKT recipients, which have been used since 2005, comprises low-dose TAC, low-dose MMF, a low-dose injection of rituximab, several sessions of plasmapheresis, and basiliximab induction.

Currently, ABO-ILKT has been accepted as a valid alternative therapy for end-stage kidney disease (ESKD) and the outcome of ABO-ILKT has become equivalent to ABO-CLKT. However, there was no report about the economic comparison among ABO-ILKT, -CLKT and -MLKT in Japan. We compared the medical costs of LKT associated with ABO-incompatibility.

[Methods]

A total of 35 patients who underwent LKT at our institute from May 2014 to October 2014; 11 ABO-CLKT, 10 -ILKT, and 14 -MLKT recipients were included in the study. They were followed for 2 years. We assessed the medical cost incurred during the transplantation surgery, the 1-year, and 2-year post transplantation (For calculation, 1USD = 110JPY).

[Results]

Overall costs incurred during the transplantation surgery for ABO-CLKT, -ILKT, and -MLKT were calculated to be 24,436–30,345 USD (median 27,668), 22,303–42,378 USD (median 32,852), and 25,462–34,876 USD (median 29,418), respectively. The post-1 year costs for ABO-CLKT, -ILKT, and -MLKT were 19,955–53,876 USD (median 27,523), 15,841–42,107 USD (median 22,589), and 17,132–47,390 USD (median 26,444), respectively.

The post-2 year costs for ABO-CLKT, -ILKT, and -MLKT were 15,388–35,100 USD (median 21,496), 13,715–28,204 USD (median 18,841) and 13,748–30,551 USD (median 18,767), respectively.

[Conclusions]

In this study, no difference was found in the medical costs associated with ABO-CLKT, -ILKT, or -MLKT. Recently, in terms of the medical cost, ABO-ILKT is an acceptable treatment for patients with ESKD.

CITATION INFORMATION: Fujimori D, Okumi M, Ungami K, Ishida H, Tanabe K. A Comparison of Medical Costs Among ABO-Compatible, -Incompatible, and -Minor Mismatched Living Kidney Transplantation: A Single-Center Study. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Fujimori D, Okumi M, Ungami K, Ishida H, Tanabe K. A Comparison of Medical Costs Among ABO-Compatible, -Incompatible, and -Minor Mismatched Living Kidney Transplantation: A Single-Center Study. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/a-comparison-of-medical-costs-among-abo-compatible-incompatible-and-minor-mismatched-living-kidney-transplantation-a-single-center-study/. Accessed March 4, 2021.

« Back to 2017 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.